International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility

Jae Ho Jung, Dae Jung Kim, Kangho Suh, Jaeeun You, Je Ho Lee, Kyung In Joung and Dong Churl Suh
Additional contact information
Jae Ho Jung: College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
Dae Jung Kim: College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
Kangho Suh: Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15217, USA
Jaeeun You: College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
Je Ho Lee: College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
Kyung In Joung: Graduate School of Public Health, Seoul National University, Seoul 08826, Korea
Dong Churl Suh: College of Pharmacy, Chung-Ang University, Seoul 06974, Korea

IJERPH, 2021, vol. 18, issue 2, 1-14

Abstract: Background: The demand for implementing a new listing scheme to expedite patient access to novel oncology drugs has increased in South Korea. This study was conducted to compare the prices of anticancer drugs between eight countries and to explore the feasibility of a ‘pre-listing and post-evaluation’ scheme to expedite patient access to oncology drugs. Methods: This study included 34 anticancer drugs, which were reimbursed between 1 January 2007 and 31 December 2017. The unit price and sales volume of the study drugs were collected from eight countries and IQVIA data, respectively. The prices were adjusted to estimate the ex-factory prices using the discount/rebate rate suggested by the Health Insurance Review Agency (HIRA). The four price indices of Laspeyres, Paasche, Fisher, and the unweighted index were calculated using the price in each country, the average price, and lowest price among the study countries. Each currency was converted using the currency exchange rate and purchasing power parity (PPP). The budget impact of implementing the proposed pre-listing and post-evaluation scheme on payers was calculated. Results: Based on the currency exchange rate, anticancer drug prices were higher in other countries (index range: 1.05–2.78) compared to Korea. The prices in Korea were similar to countries with the lowest prices. When the PPP was applied, prices were higher in the US, Germany, Italy, and Japan than in Korea (range: 1.10–2.13); however, the prices were lower in the UK, France, and Switzerland than in Korea (range: 0.72–0.99). The financial burden of implementing the pre-listing and post-evaluation scheme was calculated at 0.83% of the total anticancer drug sales value in Korea from 2013–2017. Conclusions: The prices of anticancer drugs in Korea were similar to the lowest prices among the seven other study countries. A pre-listing and post-evaluation scheme should be considered to improve patient access to novel anticancer drugs by reducing the reimbursement review time and uncertainties.

Keywords: price comparison; anticancer drugs; international price; price index; patient access (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/2/670/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/2/670/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:2:p:670-:d:480501

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().